human immunodeficiency virus News
-
BOC Sciences Becomes the Largest PseudoUridine Supplier in the World
BOC Sciences recently announces that its annual yield of pseudoUridine has reached more than 500 kilograms, which indicates that this US-based chemical and pharmaceutical company has become the largest supplier of pseudoUridine in the world. Currently, due to the severe situation of the COVID-19 pandemic, the global need for vaccines is still huge. Under this circumstance, BOC Sciences has ...
By BOC Sciences
-
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a ...
-
Alfa Chemistry Offers Varieties of Marine Biomaterials for Use in Biomedicine, Cosmetics and Nutraceuticals
The US-located chemical supplier Alfa Chemistry has recently unveiled its wide range of marine biomaterials, opening new possibilities in the fields of biomedicine, cosmetics, and nutraceuticals. With an extensive collection of marine polysaccharides, oligosaccharides, bioactive peptides, marine oils, and microalgae powders, researchers and industries alike can explore the potential of marine ...
-
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. (NASDAQ: HOOK, ...
-
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you